Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 13/20 | 0.56 |
| ▸ | GUCY1A1 | Q02108 | 5/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219535 | 0.89 | PDE5A (0.55) | ADORA3KCNH2PDE5A | |
| SCHEMBL7835258 | 0.88 | ADORA3 (0.65) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14282080 | 0.86 | ADORA3 (0.60) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174189 | 0.85 | ADORA3 (0.61) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174830 | 0.84 | ADORA3 (0.63) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6221297 | 0.84 | PDE5A (0.55) | ADORA3KCNH2PDE5A | |
| SCHEMBL14282081 | 0.84 | ADORA3 (0.59) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL27557251 | 0.84 | ADORA3 (0.60) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL4939648 | 0.83 | ADORA3 (0.64) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6222114 | 0.83 | ADORA3 (0.57) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102768-B1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | BAYER HEALTHCARE AG (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040224945-A1 | Novel substituted pyrazole derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6743798-B1 | CARDIOVASCULAR DISORDERS; VASORELAXATION, INHIBITION OF PLATELET AGGREGATION, DECREASE IN BLOOD PRESSURE; STIMULATION OF SOLUBLE GUANYLATE CYCLASE AND AN INTRACELLULAR CGMP INCREASE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224945-A1 | Novel substituted pyrazole derivatives | CYP11B2, CYP11B1, ADRB3 | ADORA3 260/4885KCNH2 1026/4885PDE5A 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.